PEG-IFN lambda: Completed Phase IIb enrollment

ZymoGenetics completed enrollment of 570 treatment-naïve patients in the international Phase II EMERGE trial comparing ribavirin plus 120, 180 and 240 µg weekly subcutaneous PEG-interferon lambda or w...